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Introduction
Patients undergoing total hip replacement (THR) may experience moderate to severe pain while most if not all of the patients undergoing total knee replacement (TKR) will have severe postoperative pain. Effective pain therapy is an important challenge for the anaesthesiologist since it may reduce pain-related problems and improve postoperative outcome. [1, 2] Although opioids are accepted as the mainstay for moderate to severe postoperative pain treatment they are generally combined with other analgesics to decrease both consumptions and opioid related side effects. [3] [4] [5] [6] [7] Dexketoprofen trometamol is a water-soluble salt of the S(+)-enantiomer of the racemic compound ketoprofen. [7] It has been shown that the anti-inflammatory and analgesic effect of ketoprofen is due entirely to the S(+)-enantiomer (dexketoprofen), while the R(-)-enantiomer is devoid of such activity. [7] There is evidence that the R(-)-enantiomer has the ulcerogenic activity and dexketoprofen produces equivalent analgesia to double dose ketoprofen with less risks of harm. [8] Lornoxicam is a member of oxicam group non-steroidal anti-inflammatory drugs (NSAIDs) with an improved gastrointestinal toxicity profile. [9] The relatively short half-life of lornoxicam is an advantage of lornoxicam over other NSAIDs because longer plasma half-lives have previously been linked to a high incidence of adverse events. [10] The aim of this prospective, randomized, and placebo controlled study was to compare the efficacy and safety of intravenous dexketoprofen trometamol 50 mg with that of 8 mg intravenous lornoxicam and placebo after major orthopedic surgery (THR or TKR).
Materials and Methods
With the approval of local ethics committee and signed informed consent of the patients, 120 American Society of Anesthesiologists (ASA) I-III patients underwent elective unilateral hip or knee replacement surgery were included in the study. Patients with endocrine disorders, severe hepatic and renal diseases, neuropathies, bleeding disorders, preexisting gastric ulcers, gastritis, and history of gastrointestinal bleeding, dementia, cooperation disability and sensitivity to dexketoprofen, lornoxicam or morphine were not included. All patients were informed about pain evaluation with visual analogue scale (VAS) and using the patient controlled analgesia (PCA) device during a preoperative visit the day before the surgery.
Anesthetic technique
All patients had 0.01 mg/kg intravenous midazolam for premedication. Heart rate (HR), peripheral oxygen saturation (SpO 2 ) and non-invasive blood pressures were monitored by Horizon XL during the surgery. During induction 2 mcg/kg fentanyl, 2-3 mg/ kg propofol were given, and trachea was intubated after vecuronium 0.1 mg/kg. During maintenance of anaesthesia 1-2% sevoflurane was applied in 40% O 2 , and 60% N 2 O. A hundred and twenty patients were randomly assigned, using sealed numbered and opaque envelopes to one of the three groups of 40 patients. The first injection was administered at the end of the surgery, with the first closing stitch and the second injection was administered 12 hours later. All study drugs were given as 2 ml solutions. In order to maintain double-blind conditions, study drugs were prepared and injected by medical staff that was not involved in pain evaluations.
Group dexketoprofen (GD):
Patients (n=40) had 50 mg intravenous dexketoprofen trometamol twice a day: first dose was applied at the end of the surgery, with the first closing stitch and the second injection was administered 12 hours later.
Group lornoxicam (GL):
Patients (n=40) had 8 mg intravenous lornoxicam twice a day: first dose was applied at the end of the surgery, with the first closing stitch and the second injection was administered 12 hours later.
Group placebo (GP):
Patients (n=40) had 2 ml intravenous saline twice a day: first dose was applied at the end of the surgery, with the first closing stitch and the second injection was administered 12 hours later.
Postoperative analgesia
In the recovery room patients were given 0.05 mg/kg intravenous morphine as required to stabilize their pain and at the same time for postoperative analgesia use of the PCA device was started (IV morphine 0.01 mg/kg bolus dose and 10 min lockout time).
Evaluation parameters
During the postoperative period, the degree of subjects' pain was evaluated with a 0-to 100 mm Visual Analog Scale (VAS). Scores were obtained at one, two, four, 6, 8, 12, and 24 hours after surgery at rest and during movement. Total morphine consumption via PCA device at the twenty fourth postoperative hours and the number of bolus demands in the first 24 hours postoperatively was recorded by an anesthesiologist who was blinded to the solution administered.
Statistical analysis
Based on a previous we calculated a group size of 34 patients would be sufficient to detect a difference of 20% cm on the VAS during movement at a threshold of 0.1 with a power of analysis 95%.
Differences among groups for the primary endpoint were tested using an analysis of variance (ANOVA). Secondary endpoints were analyzed using an ANO-VA or Kruskall-Wallis, chi-square, or McNemar test as appropriate. Differences in group demographic characteristics were tested by ANOVA or contingency table chi-square test for categorical measures. A level of p<0.05 was considered statistically significant.
Results
A hundred and twenty patients were enrolled in the study. One patient from the lornoxicam group was excluded due to PCA device failure. One patient in the control group developed fever and was given an antipyretic drug and was excluded. Therefore, a total of 118 patients were included to full-analysis population for efficacy. A comparison of groups with respect to age, sex, body weight and operative characteristics showed no statistically significant difference (Table 1) .
VAS scores at rest
At the early postoperative period the rest VAS scores of all groups were high and decreased in time; the reduction of VAS scores (≤40) of GD patients were faster while it was slowest in GP patients.
Patients in GD and GL had significantly lower VAS scores than patients in GP at 1, 2, 4, 8, 12, and 24 h postoperatively at rest. Also, the VAS values of GL patients were significantly higher than GD patients at 1, 2 and 4 h at rest (Table 2) .
VAS scores during movement
At the early postoperative period VAS scores of all the groups during movement were high and decreased in time; the reduction of VAS scores were faster in GD patients while it was slowest in GP patients (Figure 1 ).
GD patients had significantly lower VAS values than patients in GL during movement throughout the study period except the 24th h. GD patients had significantly lower VAS values than patients in GP during movement throughout the study period. GL patients had significantly lower VAS values than patients in GP at 2, 4, 6, 8, 12 , and 24 h postoperatively during movement (Figure 1 ). ter major orthopedic surgery (THR or TKR) under general anesthesia.
After surgery 20-40% of all patients experience moderate pain whilst 50-70% experience severe pain. [11] In the treatment of postoperative pain opioid drugs are used as first line drugs; but because of serious side-effects they are not used in adequate doses to treat moderate to severe pain. [12] Consumptions and the incidence of side effects opioids are reduced by combination of opioids with NSAIDs. [7] In a study comparing intramuscular dexketoprofen trometamol 50 mg with ketoprofen 100 mg and placebo in major orthopedic surgery patients Hanna et al. found out that the opioid consumptions of both dexketoprofen trometamol and ketoprofen were lower than placebo. [7] The protocol of that study is similar to the present one but there are some important differences; instead of ketoprofen,
Morphine Consumptions of the Groups
Patients in GD used 11.5 mg (range 7-16.8 mg) morphine while GL patients used 14.6 mg (range 10.6-18 mg) and GP patients used 22.9 mg (range 16.9-32 mg) (p<0.001 and GD vs. GP p<0.001, GL vs. GP p<0.001 and GD vs. GL p<0.01).
Patients in GD had a median of 16 boluses (range [12] [13] [14] [15] [16] [17] [18] [19] [20] while GL patients had a median of 20 boluses (range 16-24) and GP patients had a median of 34 boluses (range 26-36) (p<0.0001 and GD vs. GL p<0.001, GD vs. GP p<0.001 and GL vs. GP p<0.001).
Discussion
The most important finding of the present study was that IV dexketoprofen trometamol 50 mg twice a day (first dose at the end of surgery and second dose at 12th hour postoperatively) provided a better pain relief than IV lornoxicam 8 mg twice a day af- lornoxicam is used as the second NSAID and intravenous route is the route of drug application instead of intramuscular application. In that study Hanna et al. found no difference between dexketoprofen trometamol 50 mg and ketoprofen 100 mg in terms of morphine consumption which is not surprising because 1 mg dexketoprofen trometamol is accepted or found out to be equivalent to 2 mg of ketoprofen in several studies. [15, 16] In a study comparing 25 mg dexketoprofen trometamol with placebo in elective hip replacement surgery patients Iohom et al. found out that dexketoprofen trometamol was superior to placebo in terms of opioid consumption. [17] Rosenow et al. compared the analgesic efficacy and tolerability of intravenous PCA lornoxicam analgesia with that of morphine in lumbar disc surgery and concluded that lornoxicam via intravenous PCA provided statistically equivalent pain relief to that of morphine with a lower incidence of adverse events. [18] Korkmaz Dilmen et al. compared the analgesic efficacy of lornoxicam, metamizol, and paracetamol with placebo and concluded that metamizol or paracetamol, but not lornoxicam (16 mg/ day), provided effective analgesia following lumbar disc surgery. [19] The results of this study are different from the present one; but variations in the results could be due to the differences in types of surgery, drug administration routes, and PCA protocols.
In a study done on TKR patients Inan et al. compared the morphine consumptions of 32 mg lornoxicam in 48 h with placebo and found that lornoxicam administration decreased morphine consumption and morphine related side-effects without changing VAS values. [20] In the present study morphine consumption decreased with lornoxicam administration but VAS values also decreased with lornoxicam administration; variations in the results might be due to the differences in types of surgery (TKR vs. THR/ TKR), and PCA protocols.
When we look at VAS values during motion there are a few studies in the literature and in one of these studies Berti et al. compared oral dexketoprofen, oral ketoprofen, or oral paracetamol and demonstrated that in outpatients receiving arthroscopic knee surgery, the use of 75 mg/day dexketoprofen was as effective and safe as 150 mg/day racemic ketoprofen, with a better pain relief during motion compared to 2 g/day paracetamol. [21] In a study done in total hip replacement surgery patients the addition of dexketoprofen to intravenous tramadol PCA resulted in similar levels of VAS during both at rest and motion with less tramadol requirement. [22] To our knowledge this is the first study comparing dexketoprofen and lornoxicam in acute pain treatment. In the systematic review of dexketoprofen made by Moore and Barden it was stated that in all (12/12) randomized trials that compared dexketoprofen (any dose) with placebo dexketoprofen was superior to placebo and in 29/30 active comparator trials dexketoprofen was at least equivalent in efficacy to its active counterpart. [8] Leman et al. compared 25 mg oral dexketoprofen with 50 mg diclofenac in lower limb surgery and showed an earlier onset of analgesic efficacy and more reductions in mean pain scores with dexketoprofen. [22] There are some limitations of the present study. First of all the VAS values of the patients were evaluated just for 24 h and no long-term data about pain and analgesic requirements were given. Secondly it is not known that the doses of active drugs used are equipotent or not; but the doses were chosen according to the manufacturers' recommendations. These drugs are not compared with each other in major orthopedic surgery and further studies are needed comparing different doses of these drugs. Also the doses that are used in the present study are not higher than the doses used by other investigators. [7, 16, 19, 20] 
Conclusion
The results of this study show that 50 mg dexketoprofen trometamol 12 hourly IV was superior to 8 mg lornoxicam 12 hourly IV in terms of pain relief and opioid utilization for major orthopedic surgery (THR/TKR) under general anaesthesia and also both dexketoprofen trometamol and lornoxicam provided better pain relief and less analgesic requirements than placebo.
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